So, for a clear conceptualization, biochemical validation through co-immunoprecipitation (co-IP) or pull-down assays will be essential to confirm the physical interaction between FOXO proteins and the cGAS–STING complex and to characterize its regulatory relevance in NSCLC. The gene discussed is STING1; the disease is non-small cell lung carcinoma.